Toezicht op de gezondheid van de alvleesklier na diagnose van diabetes (SAFE-D)
An Interventional Study to Evaluate the cfDNA Pancreatic Cancer Test (Avantect) in the Early Detection of Pancreatic Cancer in Participants With Newly Diagnosed Diabetes Mellitus or Newly Elevated HbA1c
The goal of this interventional study is to evaluate if the novel diagnostic blood test, called Avantect can early detect pancreatic cancer in patients diagnosed with type 2 diabetes or with elevated sugar levels within the last 200 days.
Participants will:
- attend 3 study visits over 12 months time
- provide a blood sample at each study visit
- complete an anxiety questionnaire at each visit.
Studie Overzicht
Toestand
Toestand
Conditie
Conditie
Interventie / Behandeling
Interventie / Behandeling
Gedetailleerde beschrijving
Pancreatic cancer (PC) is one of the most lethal common cancers (five-year survival 5-7%). In more than 80% of patients the disease has spread before it is detected, ruling out potentially curative treatment options. Early detection offers the possibility of surgery leading to significantly improved overall survival.
There is currently no accepted screening test for pancreatic cancer. The Aventect test is designed to detect clues, or biomarkers for the presence or absence of pancreatic cancer signals in blood. The SAFE-D study will evaluate if the Avantect test can detect pancreatic cancer at an earlier more treatable stage.
People older than 50 years who have recently been diagnosed with type II diabetes have up to ten times higher-than-average risk of having pancreatic cancer without knowing.
The study will recruit 5,000 participants aged 50-84 years old diagnosed with type II diabetes or elevated Hb1Ac levels within the last 200 days from GP practices over 3 years.
Participants will have their blood samples analysed on the Avantect test as soon as possible. If a pancreatic biomarker is detected the participants will be informed and offered a standard of care diagnostic imaging scan (MRI or CT) to rule out pancreatic cancer. All participants will be followed remotely via cancer and mortality registry searches for 3 years from consent to assess any cancer diagnosed during this time.
Studietype
Studietype
Inschrijving (Geschat)
Inschrijving
Fase
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
Studiecontact
- Naam: SAFE-D Trial Manager
- Telefoonnummer: +442381205154
- E-mail: safed@soton.ac.uk
Studie Locaties
-
-
-
Ashton-under-Lyne, Verenigd Koninkrijk, OL6 6HD
- Actief, niet wervend
- Ashton Medical Group
-
Birmingham, Verenigd Koninkrijk, B14 4DU
- Werving
- Yardley Wood Health Centre
-
Contact:
- Anson-Wisniewska
- Telefoonnummer: 02380215154
- E-mail: safed@soton.ac.uk
-
Bournemouth, Verenigd Koninkrijk, BH7 7DW
- Actief, niet wervend
- Bournemouth Research Hub
-
Bromborough, Verenigd Koninkrijk, CH62 6EE
- Werving
- Eastham Group Practice
-
Contact:
- Anson-Wisniewska
- Telefoonnummer: 02380215154
- E-mail: safed@soton.ac.uk
-
London, Verenigd Koninkrijk, NW10 2PT
- Werving
- Willesden Medical Centre
-
Contact:
- Anson-Wisniewska
- Telefoonnummer: 02380215154
- E-mail: safed@soton.ac.uk
-
London, Verenigd Koninkrijk, SW1P 2PF
- Werving
- South Westminster Centre
-
Contact:
- Anson-Wisniewska
- Telefoonnummer: 02380215154
- E-mail: safed@soton.ac.uk
-
London, Verenigd Koninkrijk, W7 1DR
- Werving
- The Cuckoo Lane Practice
-
Contact:
- Anson-Wisniewska
- Telefoonnummer: 02380215154
- E-mail: safed@soton.ac.uk
-
Manchester, Verenigd Koninkrijk, M14 6WP
- Actief, niet wervend
- Bodey Medical Centre
-
Manchester, Verenigd Koninkrijk, M23 1JX
- Actief, niet wervend
- Bowland Medical Practice
-
Manchester, Verenigd Koninkrijk, M23 2SY
- Actief, niet wervend
- The Maples Medical Centre
-
Nottingham, Verenigd Koninkrijk, NG17 4JL
- Werving
- King's Mill Hospital (Sherwood Forest) Research Van
-
Contact:
- Anson-Wisniewska
- Telefoonnummer: 02380215154
- E-mail: safed@soton.ac.uk
-
Portsmouth, Verenigd Koninkrijk, PO1 3HN
- Actief, niet wervend
- Portsmouth Research Hub
-
Rossendale, Verenigd Koninkrijk, BB4 5SL
- Werving
- Hazelvalley Family Practice
-
Contact:
- Anson-Wisniewska
- Telefoonnummer: 02380215154
- E-mail: safed@soton.ac.uk
-
Ruislip, Verenigd Koninkrijk, HA4 8NX
- Werving
- Pembroke Centre (Hillingdon)
-
Contact:
- Anson-Wisniewska
- Telefoonnummer: 02380215154
- E-mail: safed@soton.ac.uk
-
Southampton, Verenigd Koninkrijk, SO30 3JB
- Werving
- Moorgreen Hospital
-
Contact:
- Anson-Wisniewska
- Telefoonnummer: 02380215154
- E-mail: safed@soton.ac.uk
-
Southampton, Verenigd Koninkrijk, SO15 33UA
- Actief, niet wervend
- Southampton Research Hub (Shirley Research Hub)
-
Uttoxeter, Verenigd Koninkrijk, ST14 8JG
- Werving
- Balance Street Health Centre
-
Contact:
- Anson-Wisniewska
- Telefoonnummer: 02380215154
- E-mail: safed@soton.ac.uk
-
Uxbridge, Verenigd Koninkrijk, UB8 1UW
- Werving
- Civic Centre
-
Contact:
- Anson-Wisniewska
- Telefoonnummer: 02380215154
- E-mail: safed@soton.ac.uk
-
Walsall, Verenigd Koninkrijk, WS6 6EW
- Werving
- Quinton Practice
-
Contact:
- Anson-Wisniewska
- Telefoonnummer: 02380215154
- E-mail: safed@soton.ac.uk
-
Weymouth, Verenigd Koninkrijk, DT4 0QE
- Actief, niet wervend
- Weymouth Research Hub
-
-
Cheshire
-
Sandbach, Cheshire, Verenigd Koninkrijk, CW11 1EQ
- Actief, niet wervend
- Ashfields Primary Care Centre
-
-
Kent
-
Maidstone, Kent, Verenigd Koninkrijk, ME16 9QQ
- Werving
- Maidstone and Tunbridge Wells NHS Trust
-
Contact:
- Anson-Wisniewska
- Telefoonnummer: 02380215154
- E-mail: safed@soton.ac.uk
-
-
Leicester Forest East
-
Leicester, Leicester Forest East, Verenigd Koninkrijk, LE3 3LW
- Werving
- Forest Medical Group
-
Contact:
- Anson-Wisniewska
- Telefoonnummer: 02380215154
- E-mail: safed@soton.ac.uk
-
-
Leicestershire
-
Kibworth Beauchamp, Leicestershire, Verenigd Koninkrijk, LE8 0LG
- Werving
- South Leicestershire Medical Group
-
Contact:
- Anson-Wisniewska
- Telefoonnummer: 02380215154
- E-mail: safed@soton.ac.uk
-
-
Staffordshire
-
Burton-on-Trent, Staffordshire, Verenigd Koninkrijk, DE14 3RH
- Werving
- Peel Croft Surgery
-
Contact:
- Anson-Wisniewska
- Telefoonnummer: 02380215154
- E-mail: safed@soton.ac.uk
-
Kingswinford, Staffordshire, Verenigd Koninkrijk, DY6 8DN
- Werving
- Kingswinford Medical Practice
-
Contact:
- Anson-Wisniewska
- Telefoonnummer: 02380215154
- E-mail: safed@soton.ac.uk
-
Leek, Staffordshire, Verenigd Koninkrijk, ST13 6QR
- Werving
- Park Medical Centre
-
Contact:
- Anson-Wisniewska
- Telefoonnummer: 02380215154
- E-mail: safed@soton.ac.uk
-
Stratford-upon-Avon, Staffordshire, Verenigd Koninkrijk, CV37 6HJ
- Werving
- Trinity Court Surgery
-
Contact:
- Anson-Wisniewska
- Telefoonnummer: 02380215154
- E-mail: safed@soton.ac.uk
-
-
Surrey
-
Brockham, Surrey, Verenigd Koninkrijk, RH3 7NJ
- Werving
- Brockwood Medical Practice
-
Contact:
- Anson-Wisniewska
- Telefoonnummer: 02380215154
- E-mail: safed@soton.ac.uk
-
Epsom, Surrey, Verenigd Koninkrijk, KT17 4BL
- Werving
- Integrated Care Partnership/ The Old Cottage Hospital
-
Contact:
- Anson-Wisniewska
- Telefoonnummer: 02380215154
- E-mail: safed@soton.ac.uk
-
Warlingham, Surrey, Verenigd Koninkrijk, CR6 9NW
- Werving
- Warlingham Green Medical Practice
-
Contact:
- Anson-Wisniewska
- Telefoonnummer: 02380215154
- E-mail: safed@soton.ac.uk
-
-
Deelname Criteria
Geschiktheidscriteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- 50 - 84 years of age at the time of enrolment (within year of birth, not month of birth)
- Confirmed type 2 DM diagnosis established within the last 200 days or an initial elevated HbA1c ≥ 48 mmol/mol or 6.5% obtained within the last 200 days. This includes people who have a first elevated HbA1c (≥ 48 mmol/mol or 6.5%) within the last 200 days, even if subsequent HbAc1 measurements return to the the normal range.
- Willing to provide up to 30 mL of blood for each study visit
- Willing and eligible to undergo MRI or CT scan
- Understands the study process and is willing to take part in the study and sign the informed consent form
Exclusion Criteria:
- Prior type I or type II DM diagnosis or an initial HbA1c ≥ 48 mmol/mol or 6.5% obtained prior to the 200-day inclusion window, except gestational elevated HbA1c.
- A history of pancreatic cancer, pancreatic neuroendocrine tumour (pNET) or Pancreatitis
- Under investigation for or confirmed pancreatic cancer
- Under investigation/surveillance for pancreatic cyst
- Any known pancreatic surgery (not including ERCP), or other major surgery requiring anaesthesia within 3 months
- Any invasive solid or haematological cancer in the past 3 years, including cancer recurrence after treatment in the last 3 years
- BMI > 40 at the time of consent
- Blood transfusion within 1 month
- Solid organ transplant recipient
- Currently pregnant
- Needing dialysis
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Diagnostisch
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Aantal wapens
Wapens en interventies
Deelnemersgroep / ArmDeelnemersgroep / Arm |
Interventie / BehandelingInterventie / Behandeling |
|---|---|
|
Experimenteel: Interventional
Participants will have their blood samples tested on the Avantect test within prioritised timeframe. The "detected" Avantect test results will be shared with the participants and their General Practitioners (GPs) to allow for further MRI or CT investigations by the local clinical team. |
Avantect test |
Wat meet het onderzoek?
Primaire uitkomstmaten
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Sensitivity of the Avantect test
Tijdsspanne: The final analysis will be carried out after 3-year follow up data has been collected for all 5,000 participants.
|
The proportion of individuals with one or more Avantect "detected" test result who have pancreatic cancer diagnosed via imaging in relation to all individuals in the study who had pancreatic cancer diagnosed. |
The final analysis will be carried out after 3-year follow up data has been collected for all 5,000 participants.
|
|
Specificity of the Avantect test
Tijdsspanne: The final analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
The proportion of individuals with one or more Avantect "not detected" test results, and no Avantect "detected" results, who did not have a pancreatic cancer diagnosis in relation to all individuals in the study who did not have a pancreatic cancer diagnosis. |
The final analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
Secundaire uitkomstmaten
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Stage shift
Tijdsspanne: The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
The proportion of pancreatic cancers cases diagnosed at stage I/II out of all participants diagnosed with pancreatic cancer between SAFE-D participants and point-estimate of the proportion from comparative data. Stage shift will be considered successful if the lower-bound of the 95% one-sided proportion in SAFE-D participants is higher than the proportion from comparative data. |
The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
|
Positive Predictive Value (PPV) of Avantect test in detecting pancreatic cancer (PC)
Tijdsspanne: The final analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
Percentage of participants with an Avantect "detected" result who have pancreatic cancer diagnosed. The analysis will be conducted with a sample size of 5,000, pancreatic cancer prevalence of 0.8%, and 5% lost from the per protocol population. There will be an expected 261 individuals with an Avantect "detected" result. 9.6% (25/261) are expected to have a PC. PPV will be considered successful if a null PPV of 5% can be ruled out at a one-sided p-value of 0.05. |
The final analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
|
Negative Predictive Value (NPV) of Avantect test in ruling out pancreatic cancer (PC)
Tijdsspanne: The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
With a sample size of 5,000, PC prevalence of 0.8%, and 5% lost from the per protocol population, there will be an expected 4,489 individuals without an Avantect "detected" result. 99.6% (4,476/4,489) are expected to not have a diagnosis of PC. NPV will be considered successful if a null NPV of 99% can be ruled out at a one-sided p-value of 0.05. |
The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
|
Resection rate of pancreatic cancer
Tijdsspanne: The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
Percentage of participants with pancreatic cancer who underwent resection. The analysis will be conducted by comparing the proportion of pancreati cancer cases that underwent resection as a treatment modality between SAFE-D participants and the point-estimate of the proportion from comparative data. Resection rate will be considered successful if the lower-bound of the 95% one-sided proportion in SAFE-D participants is higher than the proportion from comparative data. |
The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
|
Resectability
Tijdsspanne: The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
Percentage of pancreatic cancers deemed resectable by the study MDST. |
The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
Andere uitkomstmaten
Andere uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Time-to-event outcomes
Tijdsspanne: The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
To estimate the time from new onset diabetes diagnosis to pancreatic cancer diagnosis. |
The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
|
Overall survival
Tijdsspanne: The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
To estimate the overall survival of study participants. |
The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
|
Effect of the Avantect test on state anxiety over time
Tijdsspanne: The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
To assess the effect of the Avantect test on state anxiety over time. |
The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
|
High-grade neoplasia
Tijdsspanne: The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
To investigate the performance characteristics for high-grade neoplasia. |
The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
Medewerkers en onderzoekers
Sponsor
Sponsor
Medewerkers
Medewerkers
Publicaties en nuttige links
Nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Studie start
Primaire voltooiing (Geschat)
Primaire voltooiing
Studie voltooiing (Geschat)
Studie voltooiing
Studieregistratiedata
Eerst ingediend
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Eerst geplaatst
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update geplaatst
Laatste update ingediend die voldeed aan QC-criteria
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Endocriene systeemziekten
- Neoplasmata per site
- Neoplasmata
- Metabole ziekten
- Neoplasmata van het spijsverteringsstelsel
- Ziekten van het spijsverteringsstelsel
- Glucosemetabolismestoornissen
- Endocriene klierneoplasmata
- Alvleesklier Ziekten
- Voedings- en stofwisselingsziekten
- Diabetes mellitus, type 2
- Pancreasneoplasmata
- Suikerziekte
- Alvleesklierkanker, volwassen
Andere studie-ID-nummers
Andere studie-ID-nummers
- RHMGSU0292
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
product vervaardigd in en geëxporteerd uit de V.S.
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .